Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review. (February 2021)

• Record Type: Journal Article
• Authors: Monga, Neerav; Tam, Constantine; Garside, Jamie; Davids, Matthew S.; Ward, Katherine; Quigley, Joan; Parisi, Lori; Tapprich, Christoph
• Is Part Of: Critical reviews in oncology/hematology. Volume 158(2021)
• Publication Date: 2021-02
• Subjects: Immunotherapy -- Non-Hodgkin lymphoma -- Mantle cell lymphoma -- Systematic review; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2020.103212
• Languages: English
• ISSNs: 1040-8428

Abstract

Graphical abstract: Abstract: Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin's lymphoma (NHL) with a median overall survival (OS) of approximately 3–5 years. Systematic literature reviews (SLRs) identified efficacy and safety data for first-line therapies, reported in randomised controlled trials (RCTs) and non-randomised interventional studies (NRISs). Nine and 20 independent studies were included in the RCT and NRISs SLRs, respectively. Differences in the regimens and patient outcomes varied according to patient age and suitability for autologous stem cell transplantation (ASCT). In elderly patients ineligible for transplant, OS ranged from 40 months to 69.6 months. In young transplant-eligible patients, OS ranged from 53 months to 152.4 months. Despite the paucity of directly comparable evidence on the efficacy and safety of MCL therapies, these SLRs highlight that MCL remains a difficult NHL subtype to treat, with short survival highlighting the unmet need for newer treatments that improve patient outcomes.